Insider Selling: Revvity (NYSE:RVTY) Insider Sells 7,330 Shares of Stock

Key Points

• Revvity insider Tajinder Vohra sold 7,330 shares for approximately $1.03 million, reducing their position by 52.49% to 6,635 shares.
• Revvity reported quarterly EPS of $1.41, exceeding analyst expectations of $1.21, while revenue of $729.69 million also surpassed estimates; however, revenue declined 1.3% year over year.
• Shares traded at $143.60, near their 52-week high, while analysts maintained an overall “Hold” rating with an average price target of $116.57. The company also declared a quarterly dividend of $0.07 per share.

Revvity Inc. (NYSE:RVTY - Get Free Report) insider Tajinder Vohra sold 7,330 shares of the company's stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the transaction, the insider owned 6,635 shares of the company's stock, valued at approximately $934,738.80. The trade was a 52.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Revvity Stock Performance

Shares of RVTY stock traded down $3.13 during mid-day trading on Friday, hitting $143.60. The stock had a trading volume of 3,321,311 shares, compared to its average volume of 1,455,382. The firm has a market cap of $16.02 billion, a PE ratio of 68.38, a PEG ratio of 2.65 and a beta of 1.09. The company's 50-day simple moving average is $120.00 and its 200-day simple moving average is $104.45. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.80 and a quick ratio of 1.50. Revvity Inc. has a fifty-two week low of $81.22 and a fifty-two week high of $149.52.

Revvity (NYSE:RVTY - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.21 by $0.20. The business had revenue of $729.69 million for the quarter, compared to analyst estimates of $702.96 million. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The business's revenue was down 1.3% compared to the same quarter last year. During the same period in the previous year, the business posted $1.18 earnings per share. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Sell-side analysts anticipate that Revvity Inc. will post 5.36 earnings per share for the current year.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Stockholders of record on Friday, October 23rd will be issued a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, October 23rd. Revvity's dividend payout ratio (DPR) is currently 13.33%.

Hedge Funds Weigh In On Revvity

Several hedge funds have recently bought and sold shares of the company. EdgePoint Investment Group Inc. increased its position in Revvity by 3.1% during the 1st quarter. EdgePoint Investment Group Inc. now owns 8,800,863 shares of the company's stock worth $771,044,000 after purchasing an additional 265,204 shares in the last quarter. Jupiter Topco LLC acquired a new position in shares of Revvity in the second quarter valued at approximately $961,017,000. Janus Henderson Group PLC raised its position in shares of Revvity by 2.3% in the first quarter. Janus Henderson Group PLC now owns 8,348,127 shares of the company's stock valued at $731,386,000 after buying an additional 186,956 shares during the last quarter. BlackRock Inc. purchased a new position in shares of Revvity during the second quarter valued at approximately $852,070,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Revvity by 11.7% during the first quarter. Dimensional Fund Advisors LP now owns 2,917,953 shares of the company's stock valued at $255,623,000 after buying an additional 305,837 shares during the period. 86.65% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently weighed in on RVTY. Evercore reaffirmed an "outperform" rating on shares of Revvity in a report on Wednesday, August 5th. KeyCorp boosted their target price on shares of Revvity from $125.00 to $165.00 and gave the stock an "overweight" rating in a research report on Friday, September 4th. Zacks Research raised shares of Revvity from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 4th. Sanford C. Bernstein started coverage on shares of Revvity in a report on Friday, June 26th. They issued a "market perform" rating and a $115.00 price target for the company. Finally, Wall Street Zen cut shares of Revvity from a "buy" rating to a "hold" rating in a research note on Sunday, August 16th. Four investment analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $116.57.

About Revvity

Revvity, Inc is a life sciences and diagnostics company that provides technologies, products and services used by researchers, healthcare professionals and laboratories. Its offerings support applications across genomics, proteomics, cellular analysis, drug discovery, disease research and laboratory testing.

The company develops and supplies scientific instruments, reagents, consumables, software and workflow solutions. Its portfolio includes platforms for genetic and molecular analysis, imaging, high-throughput screening, biomarker research and single-cell analysis, as well as laboratory solutions used in areas such as reproductive health and newborn screening.

Revvity was established in 2023 following the separation of PerkinElmer's Applied, Food and Enterprise Services businesses from its Precision Diagnostics operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.